Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philippe Ravaud

Showing results (21-30 of 501) with videos related to

Pageof 51
Sort By:
Presse Medicale (Paris, France : 1983)|February 7, 2004
[Risk factors for gastrointestinal bleeding associated with low-dose aspirin]Jean Sibilia, Philippe Ravaud, Géraldine Marck
Journal of Clinical Epidemiology|January 9, 2009
The variability in minimal clinically important difference and patient acceptable symptomatic state values did not have an impact on treatment effect estimatesFlorence Tubach, Bruno Giraudeau, Philippe Ravaud
International Journal of Epidemiology|July 27, 2013
Commentary: Meta-epidemiology, meta-meta-epidemiology or network meta-epidemiology?Ludovic Trinquart, Agnes Dechartres, Philippe Ravaud
JAMA|December 3, 2014
Assessment of heterogeneity in meta-analyses--replyAgnes Dechartres, Ludovic Trinquart, Philippe Ravaud
Journal of Clinical Epidemiology|June 3, 2019
Consolidated Standards of Reporting Trials (CONSORT) extensions covered most types of randomized controlled trials, but the potential workload for authors was highLina Ghosn, Isabelle Boutron, Philippe Ravaud
Plos One|April 6, 2018
Patient-important outcomes in systematic reviews: Poor quality of evidenceYouri Yordanov, Agnes Dechartres, Philippe Ravaud
The Oncologist|August 19, 2022
Availability of Results of Trials Studying Pancreatic Adenocarcinoma over the Past 10 YearsAnna Pellat, Isabelle Boutron, Philippe Ravaud
BMJ Open|August 5, 2016
Live cumulative network meta-analysis: protocol for second-line treatments in advanced non-small-cell lung cancer with wild-type or unknown status for epidermal growth factor receptorPerrine Créquit, Ludovic Trinquart, Philippe Ravaud
The Journal of Rheumatology|February 14, 2003
Cardiovascular thrombotic events and COX-2 inhibitors: results in patients with osteoarthritis receiving rofecoxibBernard Bannwarth, Philippe Ravaud, Maxine Dougados
BMC Medical Research Methodology|April 14, 2006
Planning a cluster randomized trial with unequal cluster sizes: practical issues involving continuous outcomesLydia Guittet, Philippe Ravaud, Bruno Giraudeau
Pageof 51

Showing results (21-30 of 501) with videos related to

Sort By:
Pageof 51
Presse Medicale (Paris, France : 1983)|February 7, 2004
[Risk factors for gastrointestinal bleeding associated with low-dose aspirin]Jean Sibilia, Philippe Ravaud, Géraldine Marck
Journal of Clinical Epidemiology|January 9, 2009
The variability in minimal clinically important difference and patient acceptable symptomatic state values did not have an impact on treatment effect estimatesFlorence Tubach, Bruno Giraudeau, Philippe Ravaud
International Journal of Epidemiology|July 27, 2013
Commentary: Meta-epidemiology, meta-meta-epidemiology or network meta-epidemiology?Ludovic Trinquart, Agnes Dechartres, Philippe Ravaud
JAMA|December 3, 2014
Assessment of heterogeneity in meta-analyses--replyAgnes Dechartres, Ludovic Trinquart, Philippe Ravaud
Journal of Clinical Epidemiology|June 3, 2019
Consolidated Standards of Reporting Trials (CONSORT) extensions covered most types of randomized controlled trials, but the potential workload for authors was highLina Ghosn, Isabelle Boutron, Philippe Ravaud
Plos One|April 6, 2018
Patient-important outcomes in systematic reviews: Poor quality of evidenceYouri Yordanov, Agnes Dechartres, Philippe Ravaud
The Oncologist|August 19, 2022
Availability of Results of Trials Studying Pancreatic Adenocarcinoma over the Past 10 YearsAnna Pellat, Isabelle Boutron, Philippe Ravaud
BMJ Open|August 5, 2016
Live cumulative network meta-analysis: protocol for second-line treatments in advanced non-small-cell lung cancer with wild-type or unknown status for epidermal growth factor receptorPerrine Créquit, Ludovic Trinquart, Philippe Ravaud
The Journal of Rheumatology|February 14, 2003
Cardiovascular thrombotic events and COX-2 inhibitors: results in patients with osteoarthritis receiving rofecoxibBernard Bannwarth, Philippe Ravaud, Maxine Dougados
BMC Medical Research Methodology|April 14, 2006
Planning a cluster randomized trial with unequal cluster sizes: practical issues involving continuous outcomesLydia Guittet, Philippe Ravaud, Bruno Giraudeau
Pageof 51